1. The third quarterly report of Xilong Science 202/kloc-0 shows that the company's main income is 4.859 billion yuan, up 7.9% year-on-year; The net profit of returning to the mother was 65.438+0.57 billion yuan, a year-on-year increase of 262.08%; Non-net profit deducted was 43,365,438+0.20 yuan, up 23,793.38+04% year-on-year; Among them, in the third quarter of 2002/kloc-0, the company's main revenue in a single quarter was162.7 billion yuan, a year-on-year increase of 32.75%; The net profit returned to the mother in a single quarter was 24.8936 million yuan, a year-on-year increase of 42.93%; Non-net profit deducted in a single quarter was 265,438+0,822 in 500 yuan, up 33.06% year-on-year; The debt ratio is 500 1%, the investment income is/kloc-0.06 million yuan, the financial expenses are 497 19300 yuan, and the gross profit margin is 7.9%. 2. Xilong Science Co., Ltd., stock code: 002584, stock abbreviation: Xilong Science.
2. Xilong Technology Co., Ltd., formerly known as Xilong Chemical Co., Ltd., was established in 1983 and listed on the Shenzhen Stock Exchange on June 201. Xilong Technology Co., Ltd. is an enterprise mainly engaged in research and development, production and sales of chemical reagents. The company has been committed to the research, development, production and sales of chemical reagents. After more than 30 years of development, on the basis of chemical reagents, it has extended to the field of biochemical reagents, forming four business segments: general reagents, PCB electronic chemicals, ultra-clean and high-purity solvents and biochemical reagents. 3.202 1 semi-annual report shows that the main businesses of Xilong Science are chemical industry, medical industry (including instruments and diagnostic reagents) and service industry (property rent), accounting for 97.23%, 2.54% and 0.23% of revenue respectively.
3. According to the public information of Shenzhen Stock Exchange 202 1 65438, Xilong Science is listed on the Dragon and Tiger List because it belongs to the securities with a decline deviation of 7% and a turnover rate of 20%. On that day, Xilong Science closed at 8.39 yuan, up or down by -9.98%, with deviation of-10.7 1%, turnover rate of 36.86%, amplitude of1.70% and turnover of 1.265 million. On February 7th, Xilong Science 65438+ stated on the investor interaction platform that after the equity transfer is completed, Aikewei Bio and its subsidiaries will no longer be included in the consolidated statements of the company, and the company has no * * * control ability or significant influence on the remaining 13.5438+0% equity of Aikewei Bio, and will be included in other equity instruments investment in the future; The purity of our 3HP reaches 99.5%, and the price of our products is affected by many factors.